
Abstract
During an oral glucose tolerance test (OGTT) glucose and insulin levels were measured in 26 patients with prolactin-producing pituitary tumours without growth hormone excess. Basal glucose and insulin levels did not differ from the values of an age-matched control group. After glucose load the hyperprolactinaemic patients showed a decrease in glucose tolerance and a hyperinsulinaemia. Bromocriptine (CB 154), which suppressed PRL, improved glucose tolerance and decreased insulin towards normal in a second OGTT. — Human PRL or CB 154 had no significant influence on insulin release due to glucose in the perfused rat pancreas. — These findings suggest a diabetogenic effect of PRL. CB 154 might be a useful drug in improving glucose utilization in hormone-active pituitary tumours.
Item Type: | Journal article |
---|---|
Keywords: | Prolactin, insulin release, glucose tolerance, pituitary tumours, pancreas perfusions, bromocriptine |
Faculties: | Medicine |
Subjects: | 600 Technology > 610 Medicine and health |
URN: | urn:nbn:de:bvb:19-epub-8159-8 |
ISSN: | 1432-0428 |
Language: | German |
Item ID: | 8159 |
Date Deposited: | 05. Dec 2008, 12:05 |
Last Modified: | 04. Nov 2020, 12:50 |